Evaluation of the Novel XF Drugs as Bacterial Resistance Breakers

新型 XF 药物作为细菌耐药性破坏剂的评价

• 批准号: 104987
• 金额: $ 74.74万
• 依托单位: DESTINY PHARMA PLC
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104987
• 关键词: Evaluation; Novel; XF; Drugs; Bacterial

There is an urgent need for new drugs to treat infections resulting from bacteria that are now resistant to many of the current marketed antibiotics. This is a global issue encountered in low and middle-income countries (LMICs) where healthcare provisions may be less prevalent and so the impact is even greater. The jointly funded UK Department of Health and Social Care (DHSC) and Chinese Ministry of Science and Technology(MoST) Anti-Microbial Resistance (AMR) Industrial Research program aims to extend the knowledge surrounding the efficacy of novel anti-bacterial XF drugs to tackle World Health Organisation (WHO)-identified, high priority, multi-drug resistant (MDR) bacterial pathogens. The program will also examine the efficacy of these novel drugs in combination with existing, but largely ineffective antibiotics. Positive data from this study could lead to the development of a range of new medicines that could be competitively priced so as to permit patients from LMICs and China greater access to affordable medication.

目前迫切需要新的药物来治疗由细菌引起的感染，这些细菌现在对许多目前销售的抗生素具有耐药性。这是低收入和中等收入国家（LMICs）遇到的一个全球性问题，在这些国家，医疗保健服务可能不太普遍，因此影响更大。英国卫生和社会保障部（DHSC）和中国科技部（MoST）共同资助的抗微生物耐药性（AMR）工业研究项目旨在扩展有关新型抗XF药物功效的知识，以应对世界卫生组织（WHO）确定的高优先级多重耐药（MDR）细菌病原体。该项目还将检查这些新药与现有的、但基本上无效的抗生素联合使用的疗效。这项研究的积极数据可能导致开发一系列具有价格竞争力的新药，从而使中低收入国家和中国的患者能够更多地获得负担得起的药物。